Condition
IgAN - IgA Nephropathy
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (2)
P 1 (1)
P 2 (1)
Trial Status
Completed2
Not Yet Recruiting2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07730632Phase 2Not Yet RecruitingPrimary
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
NCT07674147Early Phase 1Not Yet Recruiting
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
NCT07607002CompletedPrimary
Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data
NCT03719443Phase 1Completed
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
NCT06792799Early Phase 1Recruiting
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Showing all 5 trials